Bioprocess Bags Market Size & Outlook, 2025-2033

Bioprocess Bags Market Size

The global bioprocess bags market size was valued at USD 4.91 Billion in 2024 and is expected  to grow from USD 5.43 Billion in 2025 to reach USD 12.06 Billion by 2033, exhibiting a CAGR of 10.5% during the forecast period (2025–2033).

Bioprocess bags are sterile, flexible containers used in the biotechnology, pharmaceutical, and life sciences sectors to store, process, and transport biological materials like cells, proteins, vaccines, blood products, and other biopharmaceutical substances. They are designed to maintain the integrity and sterility of their contents throughout production stages such as fermentation, cell culture, and storage, typically made from materials compatible with specific biological products.

A key factor fueling market growth is the rising demand for biologics, biosimilars, and advanced therapies like cell and gene therapies. Bioprocess bags provide an efficient, sterile, and scalable solution to these needs. In November 2024, Sartorius Stedim Biotech’s new Centre for Bioprocess Innovation in Marlborough, Massachusetts, exemplified the ongoing advancements in bioprocessing. This center fosters collaboration and the integration of Sartorius’s latest technologies, driving innovation and enhancing bioprocessing efficiency.

Technological advancements, such as real-time monitoring sensors and high-barrier films, continue to improve process efficiency and product safety. Moreover, the increasing presence of contract manufacturing organizations (CMOs) and academic research institutions is further propelling demand for scalable and disposable bioprocessing solutions. As material science continues to innovate, and with more investment flowing into biopharmaceutical R&D, new opportunities are emerging for market expansion.

Market Trends

Shift toward Single-Use Systems

The bioprocessing industry is using single-use systems, such as bioprocess bags, for their cost-effectiveness, flexibility, and reduced contamination risks. These systems eliminate the need for cleaning and sterilization, improving efficiency, especially in biologics manufacturing. They also enable faster scale-up and scale-down, leading to quicker production cycles and shorter time to market for therapies.

• For instance, in March 2022, ILC Dover LP launched liquid single-use bioprocessing bags for handling sterile liquids, expanding its product portfolio. This move supports the biopharmaceutical industry's shift toward flexible, cost-effective, and contamination-free single-use systems, covering the entire manufacturing workflow from powder containment to sterile liquid handling.

This shift towards single-use systems is boosting greater efficiency, scalability, and cost-effectiveness in biopharmaceutical manufacturing, propelling the market.

Customization of Bioprocess Bags

Customization of bioprocess bags is a growing trend, with manufacturers offering tailored solutions in sizes, materials, and features such as integrated sensors for real-time monitoring. This enhances process efficiency, ensures optimal conditions for biologics, and supports personalized medicine by providing specific configurations for individual therapies or batches.

• For instance, in June 2024, Qosina partnered with Polestar Technologies, a leader in monitoring O2, CO2, and pH levels, to enhance their product offerings. Qosina added iDOT Single-Use Sensor Bag Ports from Polestar to their portfolio, providing biopharmaceutical manufacturers with advanced, customizable bioprocess bags equipped with real-time monitoring capabilities.

Such advancement highlights the growth in innovation, ensuring greater precision, efficiency, and adaptability in biopharmaceutical manufacturing, boosting the bioprocess market growth.

To get more insights about this report Download Free Sample Report

Bioprocess Bags Market Growth Factors

Rising Demand for Biologics

The increasing demand for biologics, including monoclonal antibodies, vaccines, and cell and gene therapies, is a major driver for the global bioprocess bags market. As biopharmaceutical companies expand production to meet global healthcare needs, the adoption of single-use bioprocess bags is rising due to their efficiency, sterility, and cost-effectiveness. The growth of personalized medicine and biosimilars further fuels this demand.

• For instance, in October 2024, Johnson & Johnson announced a USD 2 billion investment to build a biologics manufacturing facility in Wilson, North Carolina. This facility will expand production capacity for its biologics portfolio and pipeline, supporting its plan to advance over 70 novel therapies and product expansions by the end of the decade.

This investment highlights the growing demand for biologics and the need for scalable bioprocessing solutions, including bioprocess bags.

Increasing Investment in Biopharmaceutical Research

Growing investments in biopharmaceutical research are fuelling demand for advanced bioprocessing solutions such as bioprocess bags. Governments, pharma companies, and biotech firms are funding biologics, biosimilars, and gene therapy development, driving the need for scalable, efficient manufacturing and single-use technologies.

• For instance, in January 2024, ICON plc launched its Optimising Biotech Funding whitepaper, highlighting strategies for biotech companies to attract and utilize investment funding. A survey of more than 130 biotech executives published by ICON revealed that 60% of respondents expected to increase R&D spending.

The rising investments in biopharmaceutical research and the growing demand for advanced bioprocessing solutions drive market growth.

Market Restraining Factors

Environmental Concerns regarding Disposable Bags

The increasing reliance on single-use bioprocess bags has raised significant environmental concerns due to the generation of plastic waste and the challenges associated with recycling these materials. Bioprocess bags are typically made from multi-layer plastic films, which are difficult to recycle because of contamination from biological substances and their complex compositions. This has led to mounting concerns regarding the environmental impact of these disposable bags. As the biopharmaceutical industry faces growing scrutiny over sustainability, companies are being pressured to reduce waste and improve waste management practices.

Market Opportunity

Development of Advanced Materials

The bioprocess bags market is witnessing significant opportunities driven by the development of advanced, durable, sterile, and sustainable materials. Innovations in multi-layer films, biodegradable polymers, and high-barrier coatings are not only enhancing the performance of bioprocess bags but also addressing critical concerns such as contamination risks and environmental sustainability. These advancements are paving the way for broader adoption in biopharmaceutical manufacturing and improving overall process efficiency.

• For instance, in April 2023, Merck launched the Ultimus Single-Use Process Container Film, designed for extreme durability and leak resistance in bioprocessing applications. Bag leaks have been a major concern for biomanufacturers. To address this, Ultimus film incorporates a proprietary woven nylon structure, enhancing bag strength, durability, and resilience. This innovation reflects the industry's effort to improve single-use system reliability while addressing environmental concerns.

Such advancements in bioprocess bag materials are not only improving the reliability and efficiency of biomanufacturing processes but also contributing to the industry's broader goal of environmental responsibility.

Regional Insights

North America holds a leading position in the global bioprocess bags market due to its robust biopharmaceutical manufacturing capabilities, high adoption of single-use technologies, and increasing investments in biologics and gene therapy production. The region’s presence of major biopharma companies, along with well-established regulatory frameworks and technological advancements in bioprocessing, drives market growth. Moreover, the region benefits from growing R&D activities, the expansion of large-scale biomanufacturing facilities, and strategic partnerships between industry players and research institutions, further boosting market dominance.

U.s. Bioprocess Bags Market Trends

The U.S. is a leader in the bioprocess bags market due to its high levels of investment in R&D in the country. In November 2024, AstraZeneca increased its full-year sales outlook due to strong demand for cancer and rare disease drugs and announced a $3.5 billion investment to expand its U.S. research and manufacturing footprint by 2026. This expansion is expected to drive the demand for advanced bioprocessing solutions, including bioprocess bags, in the region.

Asia-Pacific is expected to register the fastest CAGR due to the rapid expansion of biopharmaceutical manufacturing, increasing investments in biosimilars and vaccines, and rising demand for cost-effective single-use bioprocessing solutions. Countries such as China, India, and South Korea are witnessing significant growth in contract manufacturing organizations (CMOs) and biologics production, further boosting the demand for bioprocess bags. Moreover, government initiatives supporting local biopharma infrastructure and the emergence of new market players contribute to regional growth.

India’s bioprocess bags industry is experiencing rapid growth, fueled by the expansion of the biotechnology sector. The number of biotech startups reached approximately 6,000 by 2023, driving significant demand for bioprocessing solutions, including bioprocess bags. India’s growing capabilities in biologics production and advanced therapies are propelling the need for scalable, efficient bioprocessing technologies, positioning the country as a key market for bioprocess bags.

China’s market is rapidly expanding, driven by increased government support for biotech innovation and the growth of biopharmaceutical manufacturing. The country’s push for self-sufficiency in biomanufacturing, coupled with the establishment of advanced production facilities, is fueling the demand for bioprocess bags. Moreover, the rising demand for biologics and biosimilars continues to accelerate market growth, making China a critical player in bioprocess bags.

Japan is witnessing significant growth in its market, underpinned by investments in biopharmaceutical research and a focus on regenerative medicine. The country’s well-established pharmaceutical industry, combined with government initiatives to support biomanufacturing advancements, is driving the adoption of single-use technologies. Japan’s commitment to biotechnology innovation and its expanding biotech infrastructure are key contributing factors.

Countries Insights

• Germany– Germany’s bioprocess bags market is one of the largest in Europe, driven by the expansion of new facilities in the country. In April 2024, Merck announced an investment of over €300 million in a new research center at its global headquarters in Darmstadt, Germany. The Advanced Research Centre will focus on developing solutions for manufacturing antibodies, mRNA applications, and other biotechnological production needs, driving innovation and increasing demand for bioprocess bags.
• France- France's market is experiencing growth due to the expansion of biopharmaceutical manufacturing facilities and government funding for R&D. In June 2024, LFB Biomanufacturing initiated a €20 million facility expansion in Alès, backed by €6.5 million in government funding under the Health Innovation 2030 plan. This expansion, focused on recombinant proteins and monoclonal antibodies, will significantly drive the demand for bioprocess bags in France’s growing biotech sector.

Type

The 3D bioprocess bags segment leads the market due to their larger volume capacity, enhanced scalability, and improved mixing efficiency. These bags are ideal for large-scale biopharmaceutical production, particularly in biologics and vaccine manufacturing. Their structural design ensures better liquid handling, reduces contamination risks, and is highly compatible with advanced single-use bioreactors. These advantages make 3D bioprocess bags essential for optimizing production processes in the biopharmaceutical industry.

By Applications

The upstream process segment holds the largest share in the global market due to its widespread use in media preparation, cell culture expansion, and fermentation. The growing adoption of single-use bioreactors and disposable bioprocessing systems in biopharmaceutical manufacturing further drives demand. Upstream processes require scalable, sterile, and contamination-free solutions, making bioprocess bags vital for maintaining process efficiency and product integrity in biologics and vaccine production.

By End-User

Pharmaceutical and biopharmaceutical companies are the leading end-users in the market, driven by the increasing demand for biologics, biosimilars, and advanced therapies like cell and gene therapies. These companies are adopting single-use bioprocess bags to improve production efficiency, minimize contamination risks, and support flexible manufacturing operations. The expansion of biopharmaceutical manufacturing facilities and increased investment in biologics production further accelerates growth.

Company Market Share

Key players in the industry are focusing on adopting key business strategies such as strategic collaborations, product approvals, acquisitions, and product launches to gain a strong foothold in the market. In addition to these, companies are investing in research and development to innovate and improve bioprocessing technologies, ensuring product reliability and efficiency.

Thermos Fisher Scientific Inc.: An Emerging Player in the Market

Thermo Fisher Scientific Inc. is rapidly emerging as a key player in the global bioprocess bags market, driven by its commitment to innovation and comprehensive portfolio of bioprocessing solutions. The company has expanded its offerings to include advanced single-use bioprocess bags designed for cell culture, fermentation, and other critical biomanufacturing applications.

Recent Developments by Thermo Fisher Scientific Inc.:

• In August 2024, Thermo Fisher Scientific Inc. opened its largest single-use technology manufacturing site in Greater Nashville. The USD 105 million, 400,000-square-foot facility will help meet the rising demand for bioprocessing materials used in vaccine and cancer therapy production. This site is part of Thermo Fisher’s USD 650 million multi-year investment to expand its bioprocessing production capabilities.

List of key players in Bioprocess Bags Market

1. Thermo Fisher Scientific Inc.
2. Sartorius AG
3. Danaher Corporation
4. Merck KGaA
5. Saint-Gobain
6. Corning Incorporated
7. Entegris
8. Meissner Filtration Products, Inc.
9. PROAnalytics, LLC
10. CellBios Healthcare And Lifesciences Pvt Ltd.
11. ILC Dover LP
12. Qosina
13. Medical & Pharma
14. Cole-Parmer Instrument Company, LLC
15. VWR International, LLC
16. AbbVie

To get more findings about this report Download Market Share

Recent Developments

• June 2024 – Qosina, in partnership with Polestar Technologies, has introduced iDOT™ Single-Use Sensor Bag Ports, enhancing single-use bioprocessing. These gamma-stable bag ports enable non-invasive monitoring and integrate with Polestar’s optical sensing technology, including pH and oxygen monitoring for bioreactors. With a pre-calibrated plug-and-play design, these ports meet USP Class VI requirements and are marketed globally by Qosina to serve both small and large-scale biopharma companies.
• January 2024 – AbbVieexpanded its manufacturing capabilities with a USD 223 million expansion of its Singapore facility. This investment will enhance biologics manufacturing capacity within AbbVie’s global network, meeting the growing demand for biopharmaceutical production.

Analyst Opinion

As per our analyst, the global bioprocess bags market is poised for significant growth, driven by the rising adoption of single-use technologies in biopharmaceutical manufacturing. The increasing demand for biologics, biosimilars, and cell and gene therapies is propelling the need for efficient, contamination-free, and scalable solutions. Moreover, advancements in material science, including high-barrier films and biodegradable polymers, are improving bag durability and sustainability, meeting the growing demands for environmentally conscious production.

Despite the optimistic growth trajectory, the market does face some challenges. One notable hurdle is the rising costs associated with high-performance materials, which may impact smaller manufacturers or those with limited budgets. Moreover, the complexity of regulatory requirements for the use of single-use technologies in different regions could slow the pace of adoption. The industry is also grappling with supply chain issues and raw material shortages, which can disrupt production timelines.

Nonetheless, the expansion of contract manufacturing organizations (CMOs) and research institutions is strengthening market growth. The Asia-Pacific region, with its rapidly expanding biopharmaceutical sector and increasing investments in bioprocessing infrastructure, presents substantial opportunities. As these challenges are addressed through innovation and strategic collaborations, the market is expected to continue its upward momentum.